Why Acute Care Is Precision Medicine's Next Frontier
Precision medicine transformed oncology by recognizing that patients who look clinically similar can have dramatically different underlying biology, and that treatment should follow the biology. Acute care for critical conditions such as sepsis, pneumonia, ARDS, acute heart failure, and acute kidney injury, has not benefited from the same revolution. In this session, Bobby Reddy Jr., PhD, CEO and co-founder of Prenosis, explores why that gap has persisted and how a convergence of AI, real-time data, and regulatory momentum is finally changing what's possible.
In this webinar with Dr. Bobby Reddy, Jr. and Healthcare Innovation’s Melinda Taschetta-Millane, viewers will learn:
- Why drug development for sepsis and other critical conditions has lagged, and how patient stratification is at the root of most trial failures.
- How FDA authorization of Sepsis ImmunoScore® signals a broader shift in how regulators are approaching AI diagnostics.
- The science behind the Prenosis precision medicine platform: from real-time biological profiling to smarter clinical trials and therapeutic matching.4.What the BARDA-funded respiratory illness study reveals about the platform's reach beyond sepsis.
- The near- and long-term vision for precision medicine in acute care, and what it will take to make it a reality.
Watch this On Demand Webinar now!
Speaker
Bobby Reddy, Jr., PhD
CEO and Co-Founder
Prenosis
Bobby Reddy, Jr., Ph.D. is Co-Founder and CEO of Prenosis, a biologically-driven technology company that develops and implements integrated diagnostic-therapeutic products in acute care to improve patient outcomes. Since founding Prenosis in 2016, Bobby has led the company to achieve significant milestones, including the groundbreaking FDA marketing authorization of Sepsis ImmunoScore® in April 2024, the first-ever FDA-authorized AI diagnostic tool for sepsis, recognized as one of TIME's Best Inventions of 2024.
Previously, Bobby served as Research Scientist at the University of Illinois at Urbana-Champaign, developing electrical point-of-care biosensors and managing strategic partnerships with Taiwan Semiconductor Manufacturing Company, Abbott Diagnostics, and Intel.
Bobby holds a Ph.D. in Electrical Engineering from UIUC, an M.S. and B.S. in Electrical Engineering and a B.S. in Computer Engineering from UC Irvine. Named to Crain's Chicago Business 40 Under 40, his mission is “to see people differently – to tailor healthcare to each individual's biology.”